These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. [Study on signal transduction pathway in differentiation and apoptosis of leukemia cells induced by heat shock protein inhibitor]. Yu WJ; Rao Q; Wang M; Tian Z; Xu ZF; Wang JX Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):677-80. PubMed ID: 18399173 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and anticancer activity of geldanamycin derivatives derived from biosynthetically generated metabolites. Lee K; Ryu JS; Jin Y; Kim W; Kaur N; Chung SJ; Jeon YJ; Park JT; Bang JS; Lee HS; Kim TY; Lee JJ; Hong YS Org Biomol Chem; 2008 Jan; 6(2):340-8. PubMed ID: 18175003 [TBL] [Abstract][Full Text] [Related]
11. Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts. Schwock J; Dhani N; Cao MP; Zheng J; Clarkson R; Radulovich N; Navab R; Horn LC; Hedley DW Cancer Res; 2009 Jun; 69(11):4750-9. PubMed ID: 19458065 [TBL] [Abstract][Full Text] [Related]
12. Heat shock protein 90 inhibitor induces apoptosis and attenuates activation of hepatic stellate cells. Myung SJ; Yoon JH; Kim BH; Lee JH; Jung EU; Lee HS J Pharmacol Exp Ther; 2009 Jul; 330(1):276-82. PubMed ID: 19329756 [TBL] [Abstract][Full Text] [Related]
13. Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells. Kurashina R; Ohyashiki JH; Kobayashi C; Hamamura R; Zhang Y; Hirano T; Ohyashiki K Cancer Lett; 2009 Oct; 284(1):62-70. PubMed ID: 19464103 [TBL] [Abstract][Full Text] [Related]
14. Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation. Fionda C; Soriani A; Malgarini G; Iannitto ML; Santoni A; Cippitelli M J Immunol; 2009 Oct; 183(7):4385-94. PubMed ID: 19748980 [TBL] [Abstract][Full Text] [Related]
15. Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer. Moser C; Lang SA; Stoeltzing O Anticancer Res; 2009 Jun; 29(6):2031-42. PubMed ID: 19528462 [TBL] [Abstract][Full Text] [Related]
16. Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling. Al Shaer L; Walsby E; Gilkes A; Tonks A; Walsh V; Mills K; Burnett A; Rowntree C Br J Haematol; 2008 May; 141(4):483-93. PubMed ID: 18373709 [TBL] [Abstract][Full Text] [Related]
17. Molecular characterization of macbecin as an Hsp90 inhibitor. Martin CJ; Gaisser S; Challis IR; Carletti I; Wilkinson B; Gregory M; Prodromou C; Roe SM; Pearl LH; Boyd SM; Zhang MQ J Med Chem; 2008 May; 51(9):2853-7. PubMed ID: 18357975 [TBL] [Abstract][Full Text] [Related]
18. [Effect of HSP90 function inhibited on the telomerase and P53 mutant in breast cancer cells]. Li X; Deng HY Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Mar; 39(2):181-3. PubMed ID: 18630678 [TBL] [Abstract][Full Text] [Related]
19. Interaction of pro-apoptotic protein HGTD-P with heat shock protein 90 is required for induction of mitochondrial apoptotic cascades. Kim JY; Kim SM; Ko JH; Yim JH; Park JH; Park JH FEBS Lett; 2006 May; 580(13):3270-5. PubMed ID: 16698020 [TBL] [Abstract][Full Text] [Related]